Teva Pharmaceutical Industries (NYSE:TEVA) Releases Earnings Results, Misses Expectations By $0.06 EPS

Teva Pharmaceutical Industries (NYSE:TEVA) issued its earnings results on Wednesday. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.06), FiscalAI reports. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The business had revenue of $4.14 billion during the quarter, compared to analyst estimates of $4.02 billion. During the same period last year, the business earned $0.66 EPS. The business’s quarterly revenue was down .8% on a year-over-year basis. Teva Pharmaceutical Industries updated its FY 2026 guidance to 1.910-2.110 EPS.

Here are the key takeaways from Teva Pharmaceutical Industries’ conference call:

• Innovative products drove growth: AUSTEDO, UZEDY, and AJOVY delivered strong Q2 increases, prompting Teva to raise their combined 2026 revenue outlook by approximately $150 million at the midpoint. AUSTEDO revenue rose 40% globally, UZEDY 43%, and AJOVY 56% year over year.
• Teva raised its full-year 2026 revenue guidance midpoint by $75 million and reported $622 million of free cash flow, up 31% year over year. Management reaffirmed its targets of a 30% non-GAAP operating margin, net debt/EBITDA below 2x, and 80% cash conversion by 2027.
• The development pipeline is advancing, with potential submissions or launches including olanzapine LAI in late 2026, ecopipam for Tourette syndrome in 2027, and additional programs through 2030. Teva also expanded duvakitug development into hidradenitis suppurativa and fibrostenotic Crohn’s disease, while anti-IL-15 programs remain active in vitiligo and celiac disease.
• Generics revenue declined 15% year over year, primarily because of lower generic REVLIMID contributions, although management said the underlying generics business was broadly stable and biosimilars are becoming a growth platform. Teva expects biosimilar revenue to exceed its $800 million 2027 target.
• Management expects elevated AUSTEDO channel inventory to normalize over the next two quarters and warned that Q4 AUSTEDO revenue could decline year over year amid purchasing and pricing changes ahead of IRA implementation. Higher planned operating expenses, unfavorable foreign exchange, and the $724 million Emalex acquisition-related R&D charge also pressured reported profitability.

Teva Pharmaceutical Industries Trading Up 8.3%

Shares of TEVA stock traded up $2.62 on Wednesday, reaching $34.28. 10,992,127 shares of the stock were exchanged, compared to its average volume of 7,264,606. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. Teva Pharmaceutical Industries has a one year low of $14.99 and a one year high of $37.35. The stock has a market cap of $39.42 billion, a PE ratio of 25.73, a P/E/G ratio of 3.28 and a beta of 0.86. The stock has a 50 day moving average price of $33.19 and a 200 day moving average price of $32.68.

Analyst Ratings Changes

A number of research analysts recently commented on TEVA shares. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research note on Tuesday. Truist Financial boosted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Bank of America raised their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. Barclays upped their target price on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Insider Buying and Selling

In other news, insider Mark Sabag sold 144,180 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $34.99, for a total value of $5,044,858.20. Following the transaction, the insider directly owned 80,760 shares in the company, valued at $2,825,792.40. This trade represents a 64.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Christine Fox sold 21,258 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total value of $750,619.98. Following the sale, the executive vice president directly owned 63,647 shares of the company’s stock, valued at approximately $2,247,375.57. This trade represents a 25.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 465,931 shares of company stock worth $16,332,989. 0.54% of the stock is currently owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently modified their holdings of TEVA. Aster Capital Management DIFC Ltd acquired a new position in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd raised its holdings in Teva Pharmaceutical Industries by 567.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock worth $42,000 after purchasing an additional 1,134 shares during the period. Global Retirement Partners LLC raised its holdings in Teva Pharmaceutical Industries by 27.3% in the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after purchasing an additional 292 shares during the period. Advocate Investing Services LLC bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth $53,000. Finally, DV Equities LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $69,000. 54.05% of the stock is owned by institutional investors.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Innovative brands delivered strong growth. Teva reported second-quarter revenue of approximately $4.1 billion, ahead of the $4.02 billion consensus estimate. Its three key innovative brands grew 43% year over year in local-currency terms to more than $1 billion, supporting the company’s strategy of shifting its portfolio toward higher-growth products. Teva Delivers Strong Q2 Results and Raises Outlook
• Positive Sentiment: UZEDY momentum prompted a higher outlook. UZEDY U.S. sales rose 43% year over year to a record $77 million in the quarter. Teva raised its 2026 UZEDY revenue forecast to $270 million–$290 million from $250 million–$280 million, reinforcing expectations for growth from long-acting injectable treatments. UZEDY Record Q2 Net Sales and Outlook
• Positive Sentiment: Trading activity and analyst sentiment were supportive. Call-option volume was about 136% above its average daily level, indicating increased bullish speculation. Piper Sandler also raised its price target to $44 and maintained an overweight rating. The company’s broader branded-drug pipeline has further attracted investor attention.
• Neutral Sentiment: Teva raised its 2026 revenue guidance to $16.5 billion–$16.9 billion, broadly in line with the $16.7 billion consensus. The company also raised outlooks for its three key innovative brands.
• Negative Sentiment: Profitability and generics remained concerns. Quarterly EPS of $0.02 missed the $0.08 consensus, while revenue declined about 1% year over year, mainly because of lower generics sales. Full-year EPS guidance of $1.91–$2.11 is below the $2.17 analyst consensus, limiting the upside from the revenue outlook. Teva Second-Quarter Earnings Report

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.